SVB Securities Maintains Their Buy Rating on Prometheus Biosciences (RXDX)

SVB Securities analyst David Risinger maintained a Buy rating on Prometheus Biosciences (RXDXResearch Report) on July 18. The company’s shares closed last Tuesday at $30.76.

According to, Risinger is a 2-star analyst with an average return of 2.0% and a 53.3% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Horizon Therapeutics, and Theravance Biopharma.

Prometheus Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $52.20.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $51.96 and a one-year low of $19.79. Currently, Prometheus Biosciences has an average volume of 487.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Prometheus Biosciences Inc is a biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of…

Read More on RXDX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More